Adial pharmaceuticals inc

US StockHealth Care

ADIL AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a low value rating. If your investment strategy is value-oriented and you have long-term positions, it's crucial to adhere to your exit plan and consider reducing holdings.

ADIL Current Performance

-14.18%

Adial pharmaceuticals inc

0.85%

Avg of Sector

-0.21%

S&P500

Top 10 High Relevance to ADIL

  • JANX Janux therapeutics inc
    Value -Trend 5Swing Trading 3Whale Interest 1Dividend 1
    See more

ADIL Profile

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company's drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company's AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.

Price of ADIL